Janux Therapeutics Achieves $10 Million Milestone as First Patient Dosed in Merck Collaboration Trial

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (Nasdaq: JANX...

August 06, 2025 | Wednesday | News
Bristol Myers Squibb’s Breyanzi Granted FDA Priority Review for Relapsed or Refractory Marginal Zone Lymphoma

Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results fro...

August 05, 2025 | Tuesday | News
Cytiva’s Ludovic Brellier on Future-Ready Biomanufacturing with the ÄKTA readyflux TFF System 500

As advanced modalities like mRNA and viral vectors reshape the biomanufacturing landscape, Cytiva is scaling innovation to meet evolving demands. In this e...

August 05, 2025 | Tuesday | Interaction
Akeso Doses First Patient in Pivotal Phase III Trial of Ivonescimab for IO-Resistant NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMO...

July 31, 2025 | Thursday | News
Revna Biosciences and AstraZeneca Transform Lung Cancer Care in Ghana with Precision Therapy Rollout

The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial...

July 31, 2025 | Thursday | News
IntraBio’s AQNEURSA® Receives Positive CHMP Opinion for Niemann-Pick Type C, Paving Way for European Approval

AQNEURSA® could offer a new frontline treatment for NPC patients in Europe CHMP recommendation based on Phase III pivotal trial data and extensi...

July 31, 2025 | Thursday | News
VedTechBio Advances AI Drug Discovery with RxAgentAI™, Joins Forces with AlphaMeld to Accelerate Therapeutic Development

VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced major enhancements to its RxAgentAI™ platform cutting drug di...

July 31, 2025 | Thursday | News
BriaCell and BriaPro Unveil TILsRx Platform to Advance Next-Generation Multivalent Immunotherapies for Cancer

BriaCell Therapeutics Corp. a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned s...

July 30, 2025 | Wednesday | News
AscellaHealth and Abeona Therapeutics Partner to Power Seamless Launch of ZEVASKYN™ Gene Therapy

AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partn...

July 30, 2025 | Wednesday | News
GH Research Reports 73% Remission in TRD with GH001; Global Pivotal Trial Set for 2026

Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months...

July 25, 2025 | Friday | News
Matchpoint Therapeutics Secures Major Partnership with Novartis for Precision Covalent Inhibitor Development

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option ex...

July 25, 2025 | Friday | News
Clearside Biomedical Secures Health Canada Approval for XIPERE® in Treating Uveitic Macular Oedema

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

July 25, 2025 | Friday | News
Cytiva Launches ÄKTA readyflux TFF System 500 to Advance Low-Volume Therapeutic Manufacturing

Cytiva, a Danaher company and a leader in the life sciences industry, is expanding its ÄKTA portfolio with the addition of a system designed to opti...

July 24, 2025 | Thursday | News
HMNC and Spruce Launch Phase 2 TAMARIND Trial to Explore Precision Treatment for Depression

HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: S...

July 23, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close